<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26572537</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of molecular neuroscience : MN</Title><ISOAbbreviation>J Mol Neurosci</ISOAbbreviation></Journal><ArticleTitle>Clinical Trials in Spinal and Bulbar Muscular Atrophy-Past, Present, and Future.</ArticleTitle><Pagination><StartPage>379</StartPage><EndPage>387</EndPage><MedlinePgn>379-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12031-015-0682-7</ELocationID><Abstract><AbstractText>Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease, is a rare adult-onset lower motor neuron disorder with a classic X-linked inheritance pattern. It is caused by the abnormal expansion of the CAG-repeat tract in the androgen receptor gene. Despite important progress in the understanding of the molecular pathogenesis and the availability of a broad set of model organisms, successful translation of these insights into clinical interventions remains elusive. Here we review the available information on clinical trials in SBMA and discuss the challenges and pitfalls that impede therapy development. Two important factors are the variability of the complex neuro-endocrinological phenotype and the comparatively low incidence of the disease that renders recruitment for clinical trials demanding. We propose that these challenges can be and need to be overcome by fostering closer collaborations between clinical research centers, the patient communities and the industry and non-industry sponsors of clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weydt</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2344-5662</Identifier><AffiliationInfo><Affiliation>Clinic of Neurology, Ulm University, Ulm, 89081, Germany. patrick.weydt@uni-ulm.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagnelli</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clinic of Central and Peripheral Degenerative Neuropathies Unit, IRCCS Foundation, "C. Besta" Neurological Institute, Via Celoria 11, Milan, 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbohm</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinic of Neurology, Ulm University, Ulm, 89081, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Neuromuscular Diseases and Sobell Department for Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradat</LastName><ForeName>Pierre-Fran&#xe7;ois</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, UPMC Univ Paris 06, CNRS, INSERM, Laboratoire d'Imagerie Biom&#xe9;dicale, Paris, F-75013, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement des Maladies du Syst&#xe8;me Nerveux, APHP H&#xf4;pital Piti&#xe9;-Salp&#xea;triere, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Clinic of Neurology, Ulm University, Ulm, 89081, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pareyson</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clinic of Central and Peripheral Degenerative Neuropathies Unit, IRCCS Foundation, "C. Besta" Neurological Institute, Via Celoria 11, Milan, 20133, Italy. davide.pareyson@istituto-besta.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FRATTA/JAN15/946-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008606/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mol Neurosci</MedlineTA><NlmUniqueID>9002991</NlmUniqueID><ISSNLinking>0895-8696</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000726" MajorTopicYN="N">Androgen Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009465" MajorTopicYN="N">Neuromuscular Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Kennedy disease</Keyword><Keyword MajorTopicYN="N">Spinal and bulbar muscular atrophy</Keyword><Keyword MajorTopicYN="N">Therapy development</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26572537</ArticleId><ArticleId IdType="doi">10.1007/s12031-015-0682-7</ArticleId><ArticleId IdType="pii">10.1007/s12031-015-0682-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuron. 2009 Aug 13;63(3):277-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19679066</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1998 Sep;153(3):695-701</Citation><ArticleIdList><ArticleId IdType="pubmed">9736019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2011 Feb;10(2):140-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2013 Jul;50(3):514-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23420040</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromuscul Disord. 2015 Oct;25(10):802-12</Citation><ArticleIdList><ArticleId IdType="pubmed">26206601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2010 Sep;9(9):875-84</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2013 Jun 4;80(23):2095-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23645595</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2009 Jan 27;72(4):317-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19171827</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2012 Dec;99(3):257-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22668795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2006 Mar;59(3):520-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16358333</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Dis Primers. 2015 Apr 23;1:15005</Citation><ArticleIdList><ArticleId IdType="pubmed">27188817</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2006 Jun;129(Pt 6):1446-55</Citation><ArticleIdList><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1991 Jul 4;352(6330):77-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2008 Apr;88(2):729-67</Citation><ArticleIdList><ArticleId IdType="pubmed">18391178</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromuscul Disord. 2015 Jul;25(7):554-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25913211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2009 Feb;65(2):140-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Apr;69(4):436-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22158719</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Aug 13;63(3):316-28</Citation><ArticleIdList><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Aug 14;8(8):e70993</Citation><ArticleIdList><ArticleId IdType="pubmed">23967145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2015 Nov 1;24(21):5985-94</Citation><ArticleIdList><ArticleId IdType="pubmed">26231218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Transl Neurol. 2015 Jul;2(7):739-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26273686</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2014 Jun 10;82(23 ):2077-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24814851</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroepidemiology. 2013;41(2):118-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2007 Jan 2;68(1):59-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17200494</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Jun;9(6):768-73</Citation><ArticleIdList><ArticleId IdType="pubmed">12754502</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2012 Dec;99(3):246-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22609045</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>